Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy.
2025
2024
2023
2022
2021
2020
2019
-
Apr 18,2025
HuidaGene Selected for Presidential Symposium at ASGCT 2025 Annual Meeting, Showcasing 13 Abstracts Demonstrating Breakthroughs in Gene Therapy
Learn More
-
Apr 11,2025
HuidaGene at CRISPR MEDiCiNE 2025: A Celebration of Progress, Promise, and Patients
Learn More
-
Apr 09,2025
HuidaGene Announces Broader Adoption of hfCas12Max Through Sublicensing Agreement to Advance Clinical Cell Therapy Programs
Learn More
-
Apr 01,2025
HuidaGene Therapeutics to Present at Multiple Key Conferences Highlighting Advances in CRISPR-based Therapies
Learn More
-
Mar 03,2025
HuidaGene Therapeutics to Present at Multiple Key Conferences Highlighting Advances in CRISPR-based Therapies
Learn More
-
Jan 08,2025
European Medicines Agency Issues Positive Opinion on HuidaGene's Triple-Designation HG004 Orphan Designation Application
Learn More
-
Dec 12,2024
HuidaGene Therapeutics Announces Landmark Publication in Nature Neuroscience Highlighting HG204’s Potential as First RNA-editing Therapy for MECP2 Duplication Syndrom
Learn More
-
Dec 12,2024
HuidaGene Therapeutics Initiates M.U.S.C.L.E. Clinical Trial of HG302 for Duchenne Muscular Dystrophy and Completes First Patient Dosed
Learn More
-
Dec 06,2024
HuidaGene Therapeutics Announced First Patient Dosed in the HERO Clinical Trial of HG204 for MECP2 Duplication Syndrome
Learn More